Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This study found that topical calcipotriol lotion resulted in hair regrowth in 59.1% of alopecia areata patients, with better response observed in those with lower serum vitamin D levels.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

In this study, traditional treatment for pediatric alopecia areata was highly effective, with all patients achieving full hair regrowth. Tofacitinib and microneedling were less effective but are viable options for severe cases, while adverse effects were mild across all treatments.

This study observed that patients with acute alopecia areata treated with Janus kinase inhibitors achieved a higher rate of complete hair regrowth by week 24 compared to those with non-acute disease, highlighting the benefits of early intervention.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

This study observed that dupilumab led to significant hair regrowth and was well-tolerated in children with both alopecia areata and atopic dermatitis, showing promise as a safe treatment option for pediatric patients with associated atopy.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

This study developed a simplified multidimensional assessment scale for alopecia areata severity and systemic treatment initiation among Chinese patients, achieving expert consensus on relevant clinical indicators and conditions.

In this clinical study involving individuals with localized alopecia areata, TrA injections were found to significantly outperform MTX, leading to better hair regrowth and higher patient satisfaction, though both treatments had similar mild side effects.

In this study of 18 children with moderate to severe alopecia areata in Brazil, mesalazine treatment showed varied responses, with 14 patients completing evaluations and two not responding after six months, amidst treatment challenges like relocation and the COVID-19 pandemic.

This study found that phototherapy was more effective for patients with the multiple or totalis types of alopecia areata, with whole-body phototherapy potentially benefiting those with refractory universalis type.

This case report describes a 22-month-old with alopecia universalis who showed improved hair growth after receiving combination therapy with minoxidil, corticosteroids, and excimer laser.

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

This study found that oral tofacitinib achieved significant hair regrowth in children with moderate to severe alopecia areata, with 72.2% reaching a 75% improvement and 52.8% achieving complete regrowth, though some patients did not respond and further research is needed on the treatment's long-term effects.

In this study, 37.5% of alopecia areata patients treated with tofacitinib were identified as super-responders, with significant predictors for this status being older age and no prior JAK inhibitor treatment, leading to faster and sustained hair regrowth.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

Calcipotriol may effectively treat hair loss in alopecia areata, working better in children than adults.

This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.

This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.